Orchid Pharma Limited (NSE:ORCHPHARMA) — Market Cap & Net Worth
Market Cap & Net Worth: Orchid Pharma Limited (ORCHPHARMA)
Orchid Pharma Limited (NSE:ORCHPHARMA) has a market capitalization of $550.18 Million (Rs50.87 Billion) as of September 16, 2026. Listed on the NSE stock exchange, this India-based company holds position #11828 globally and #591 in its home market, demonstrating a 7.32% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Orchid Pharma Limited's stock price Rs1003.05 by its total outstanding shares 50719105 (50.72 Million). Also see Orchid Pharma Limited assets under control for a full breakdown of the balance sheet.
Orchid Pharma Limited Market Cap History: 2015 to 2026
Orchid Pharma Limited's market capitalization history from 2015 to 2026. Data shows growth from $35.79 Million to $550.18 Million (29.14% CAGR). Also see ORCHPHARMA cash generation efficiency for how efficiently the company converts equity into cash flow.
Orchid Pharma Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Orchid Pharma Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ORCHPHARMA share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.07x
Orchid Pharma Limited's market cap is 0.07 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.68x
Orchid Pharma Limited's market cap is 2.68 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $10.26 Million | $7.97 Billion | -$4.95 Billion | 0.00x | N/A |
| 2018 | $2.63 Million | $6.83 Billion | -$3.53 Billion | 0.00x | N/A |
| 2019 | $2.99 Million | $6.00 Billion | $694.08 Million | 0.00x | 0.00x |
| 2020 | $67.60 Million | $4.84 Billion | -$1.31 Billion | 0.01x | N/A |
| 2021 | $216.61 Million | $4.50 Billion | -$1.17 Billion | 0.05x | N/A |
| 2022 | $199.68 Million | $5.60 Billion | -$19.51 Million | 0.04x | N/A |
| 2023 | $390.81 Million | $6.66 Billion | $463.18 Million | 0.06x | 0.84x |
| 2024 | $991.18 Million | $8.19 Billion | $921.66 Million | 0.12x | 1.08x |
| 2025 | $416.29 Million | $9.22 Billion | $996.57 Million | 0.05x | 0.42x |
| 2026 | $550.18 Million | $8.11 Billion | $205.47 Million | 0.07x | 2.68x |
Competitor Companies of ORCHPHARMA by Market Capitalization
Companies near Orchid Pharma Limited in the global market cap rankings as of September 16, 2026. Review ORCHPHARMA intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Orchid Pharma Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #627 globally with a market cap of $44.32 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #639 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Haleon plc (NYSE:HLN): Ranked #662 globally with a market cap of $41.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #627 | GALDERMA GROUP AG | NYSE:GALDY | $44.32 Billion | $38.01 |
| #639 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €15.60 |
| #662 | Haleon plc | NYSE:HLN | $41.35 Billion | $9.39 |
Orchid Pharma Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Orchid Pharma Limited's market cap moved from $35.79 Million to $ 550.18 Million, with a yearly change of 29.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs550.18 Million | +32.16% |
| 2025 | Rs416.29 Million | -58.00% |
| 2024 | Rs991.18 Million | +153.62% |
| 2023 | Rs390.81 Million | +95.71% |
| 2022 | Rs199.68 Million | -7.81% |
| 2021 | Rs216.61 Million | +220.41% |
| 2020 | Rs67.60 Million | +2161.47% |
| 2019 | Rs2.99 Million | +13.54% |
| 2018 | Rs2.63 Million | -74.33% |
| 2017 | Rs10.26 Million | -30.87% |
| 2016 | Rs14.84 Million | -58.54% |
| 2015 | Rs35.79 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 15th, 2026 the market cap of Orchid Pharma Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $550.18 Million USD |
| MoneyControl | $550.18 Million USD |
| MarketWatch | $550.18 Million USD |
| marketcap.company | $550.18 Million USD |
| Reuters | $550.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Orchid Pharma Limited
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, m… Read more